Clinical Trial Update: An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 [Phase 2]

View source ↗

Summary

This is an update on a Phase 2 open-label dose-escalation study evaluating the safety and pharmacokinetics of the oral drug PRX-112 in Gaucher disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease

Drugs mentioned

• PRX-112

Snippet

Sponsor: Protalix | Conditions: Gaucher Disease | Phase 2 | Status: COMPLETED